How to offer hormone therapy online
Hormone care is one of the fastest-growing telehealth categories — and one of the most operationally demanding. The programs that last are built around labs and monitoring, not just prescriptions.
Photograph via UnsplashOnline hormone therapy is labs-first medicine: baseline panels before therapy, re-tests around every dose change, and monitoring for the life of the prescription. TRT adds controlled-substance requirements (EPCS, DEA alignment, stricter state rules), which is why many programs sequence women’s health first. Programs that treat the re-test as the product’s heartbeat retain; programs that treat labs as a checkout add-on churn.
Why hormone therapy is a different animal from GLP-1s
Weight care runs on a fairly standard protocol. Hormone care does not: menopause care, testosterone replacement, and thyroid optimization each involve individualized dosing, meaningful contraindication screening, and therapy decisions that depend on lab values rather than symptoms alone. That makes hormone programs harder to commoditize — and more defensible for the brands and clinics that do them well.
The controlled-substance wrinkle
Testosterone is a Schedule III controlled substance. The moment TRT is on your menu, your program needs EPCS (identity-proofed prescribers, two-factor prescription signing), DEA registrations aligned with where you prescribe, PDMP checks where states require them, and telehealth prescribing rules that are stricter — and shift more often — than for non-controlled medications. Many "hormone" startups quietly launch women's-health-only first for exactly this reason. It is a legitimate sequencing strategy; just make it a decision rather than a discovery.
Labs are the product, not a step
A credible hormone program is built around a testing cadence: baseline panels before therapy, re-tests after dose changes, and periodic monitoring for the life of the prescription. Operationally that means in-network draw sites or at-home kits, results flowing back into the chart automatically, clinician review with documented decisions, and patient-facing explanations that turn lab values into a story. Programs that treat labs as a checkout add-on churn; programs that treat the retest as the product's heartbeat retain.
Monitoring cadence and the refill loop
| Phase | Clinical activity | What defines success |
|---|---|---|
| Initiation | Intake → baseline labs → clinician consult (state rules decide sync vs. async) → first prescription | Days from signup to first dose |
| Titration window | Follow-up labs and dose adjustments — the most clinician touches and the most patient anxiety | Lab-to-decision turnaround; this period defines your reviews |
| Steady state | Refills gated on periodic labs and check-ins | Monitoring compliance — the gate is good medicine and your retention rhythm |
Common failure modes
- Launching TRT without EPCS plumbing, then scrambling when the first prescription cannot be signed.
- Underpricing the monitoring: labs and clinician time recur; a one-time consult fee cannot carry them.
- Letting refills continue when patients skip monitoring labs — the exact pattern boards look for.
- One national protocol that ignores state modality differences for initial visits.
On Lithos, hormone therapy is a care plan category with labs built in: order panels (draw site or at-home), results land in the chart, clinicians manage titration, and EPCS handles controlled prescriptions — all behind your brand, via one API.
Frequently asked questions
Can testosterone be prescribed via telehealth?
Where state and federal rules allow — testosterone is Schedule III, so prescribing requires EPCS, appropriate DEA registration, PDMP checks where required, and stricter visit-modality rules that vary by state.
Why do hormone programs require so many labs?
Because therapy decisions depend on lab values, not symptoms alone: baselines rule out contraindications, and re-tests confirm each dose change is working safely. The cadence is the standard of care.
How is hormone care different from a GLP-1 program?
GLP-1 care runs on a fairly standard titration protocol; hormone care is individualized against labs, involves more contraindication screening, and (for TRT) adds controlled-substance infrastructure.
Can we launch women’s hormone care first and add TRT later?
Yes — it is a common and legitimate sequencing, since it defers the EPCS and controlled-substance stack. Just make it an explicit decision with the TRT requirements mapped, not a surprise.
Get the Journal by email
Our best guides on building compliant telehealth programs — a couple a week, unsubscribe any time.
How to start a peptide business in 2026: the compliant playbook
The clinical model that makes a peptide program lawful, the pharmacy bench that supplies it, what you can market today, and how to build for the bulks list.
Read the guide
The GLP-1 maintenance phase: what programs do when patients reach goal
The four clinician-directed maintenance patterns, how to price the tier, and why programs without one hand their best patients to competitors.
Read the guide
Launching a sexual health telehealth program: the async-first playbook
The cardiac screening that matters, the state rules, engineered discretion, and the men’s-health bundle that follows.
Read the guideFrom first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.